{"entity":{"id":"nct04691804","kind":"trial","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver","aka":[],"tldr":"A phase 3 trial of Abiraterone acetate, Prednisone in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","summary":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT04691804 by Jiangsu HengRui Medicine Co., Ltd., with 496 participants enrolled, started 2021-03-18 and due to reach its primary completion in 2026-12-31. Interventions recorded: Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04691804","url":"https://clinicaltrials.gov/study/NCT04691804"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["androgen-deprivation"],"targets":[],"drugs":["abiraterone","prednisone"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04691804","phase":"3","setting":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","participation":[{"nct":"NCT04691804","source":"https://clinicaltrials.gov/study/NCT04691804","fetchedAt":"2026-10-07T16:53:25.283Z","studySha256":"da7360bfac5aea995f2d61a1b4f227e566a53061cca5d9e292dd68ce378dff45","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2024-12-31","leadSponsor":"Jiangsu HengRui Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":496,"enrolmentType":"ACTUAL","siteCount":147,"recruitingSiteCount":0,"countries":["Australia","Belgium","China","Czechia","France","Hungary","Poland","Russia","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2021-03-18","startedType":"actual","enrolled":496,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04691804/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}